AR118371A2 - Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina - Google Patents
Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-aminaInfo
- Publication number
- AR118371A2 AR118371A2 ARP200100726A ARP200100726A AR118371A2 AR 118371 A2 AR118371 A2 AR 118371A2 AR P200100726 A ARP200100726 A AR P200100726A AR P200100726 A ARP200100726 A AR P200100726A AR 118371 A2 AR118371 A2 AR 118371A2
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- preparation
- aminooxetan
- benzothiazepin
- quinazolin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La presente se refiere a un procedimiento para la preparación de un compuesto de fórmula (1) y sales de adición farmacéuticamente aceptables del mismo, que resulta útil para la profilaxis y tratamiento de la infección por virus sincitial respiratorio (VSR) en un mamífero o ser humano.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2014/071331 | 2014-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118371A2 true AR118371A2 (es) | 2021-09-29 |
Family
ID=52358790
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100146A AR099134A1 (es) | 2014-01-24 | 2015-01-20 | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
ARP200100726A AR118371A2 (es) | 2014-01-24 | 2020-03-16 | Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100146A AR099134A1 (es) | 2014-01-24 | 2015-01-20 | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
Country Status (20)
Country | Link |
---|---|
US (2) | US10005770B2 (es) |
EP (2) | EP3248969B1 (es) |
JP (1) | JP6397501B2 (es) |
KR (1) | KR101841866B1 (es) |
CN (2) | CN109879837B (es) |
AR (2) | AR099134A1 (es) |
AU (1) | AU2015208244B2 (es) |
BR (1) | BR112016016978B1 (es) |
CA (1) | CA2934225C (es) |
ES (2) | ES2788900T3 (es) |
HR (2) | HRP20200680T1 (es) |
IL (1) | IL245882B (es) |
MX (1) | MX368110B (es) |
MY (1) | MY176210A (es) |
NZ (1) | NZ721534A (es) |
PL (2) | PL3097098T3 (es) |
RU (1) | RU2664643C2 (es) |
SG (1) | SG11201605916QA (es) |
SI (2) | SI3248969T1 (es) |
WO (1) | WO2015110446A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016184832A1 (en) | 2015-05-20 | 2016-11-24 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
CN108290882B (zh) * | 2015-07-16 | 2021-07-06 | 豪夫迈·罗氏有限公司 | 用于治疗呼吸道合胞病毒感染的4-喹唑啉胺衍生物的晶形 |
PL3324977T3 (pl) | 2015-07-22 | 2022-11-14 | Enanta Pharmaceuticals, Inc. | Pochodne benzodiazepiny jako inhibitory rsv |
MX2018005890A (es) | 2015-11-12 | 2018-08-15 | Hoffmann La Roche | Composiciones para tratar atrofia muscular espinal. |
ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
CN108137579B (zh) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
CN108017599B (zh) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法 |
EA201992878A1 (ru) | 2017-06-05 | 2020-05-08 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни хантингтона |
BR112019027717A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
CN112135815A (zh) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
US11254664B2 (en) | 2019-03-18 | 2022-02-22 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as RSV inhibitors |
KR20220101083A (ko) | 2019-10-04 | 2022-07-19 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스 헤테로사이클릭 화합물 |
US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
WO2021083290A1 (en) * | 2019-10-31 | 2021-05-06 | Shanghai Ark Biopharmaceutical Co. Ltd. | Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same |
CN113149977A (zh) * | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
CN111518055A (zh) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用 |
CN111548325A (zh) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
CN111620838A (zh) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
CN111574475B (zh) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用 |
US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
EP4298103A1 (en) | 2021-02-26 | 2024-01-03 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
SE9901573D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
CA2516329A1 (en) * | 2003-02-21 | 2004-09-02 | Pharmacia & Upjohn Company Llc | Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them |
ATE372324T1 (de) * | 2003-04-30 | 2007-09-15 | Inst For Pharm Discovery Inc | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen |
DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
JP4899385B2 (ja) * | 2005-09-06 | 2012-03-21 | 宇部興産株式会社 | 3−アミノメチルオキセタン化合物の製法 |
TW201215387A (en) * | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
US8871756B2 (en) * | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
MX342153B (es) | 2011-10-11 | 2016-09-15 | Hoffmann La Roche | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. |
CN105392787B (zh) * | 2013-05-14 | 2017-11-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚 |
JP2016518421A (ja) * | 2013-05-14 | 2016-06-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール |
-
2015
- 2015-01-20 AR ARP150100146A patent/AR099134A1/es active IP Right Grant
- 2015-01-21 ES ES15700600T patent/ES2788900T3/es active Active
- 2015-01-21 CN CN201910222238.1A patent/CN109879837B/zh active Active
- 2015-01-21 PL PL15700600T patent/PL3097098T3/pl unknown
- 2015-01-21 ES ES17176794T patent/ES2789798T3/es active Active
- 2015-01-21 RU RU2016133187A patent/RU2664643C2/ru active
- 2015-01-21 CA CA2934225A patent/CA2934225C/en active Active
- 2015-01-21 SI SI201531184T patent/SI3248969T1/sl unknown
- 2015-01-21 EP EP17176794.0A patent/EP3248969B1/en active Active
- 2015-01-21 BR BR112016016978-6A patent/BR112016016978B1/pt active IP Right Grant
- 2015-01-21 MX MX2016009514A patent/MX368110B/es active IP Right Grant
- 2015-01-21 CN CN201580005504.5A patent/CN106414436B/zh active Active
- 2015-01-21 PL PL17176794T patent/PL3248969T3/pl unknown
- 2015-01-21 SG SG11201605916QA patent/SG11201605916QA/en unknown
- 2015-01-21 SI SI201531193T patent/SI3097098T1/sl unknown
- 2015-01-21 KR KR1020167020106A patent/KR101841866B1/ko active IP Right Grant
- 2015-01-21 MY MYPI2016702654A patent/MY176210A/en unknown
- 2015-01-21 NZ NZ721534A patent/NZ721534A/en unknown
- 2015-01-21 WO PCT/EP2015/051066 patent/WO2015110446A1/en active Application Filing
- 2015-01-21 AU AU2015208244A patent/AU2015208244B2/en active Active
- 2015-01-21 EP EP15700600.8A patent/EP3097098B1/en active Active
- 2015-01-21 JP JP2016548177A patent/JP6397501B2/ja active Active
-
2016
- 2016-05-26 IL IL245882A patent/IL245882B/en active IP Right Grant
- 2016-07-21 US US15/216,501 patent/US10005770B2/en active Active
-
2018
- 2018-05-24 US US15/988,570 patent/US10253022B2/en active Active
-
2020
- 2020-03-16 AR ARP200100726A patent/AR118371A2/es unknown
- 2020-04-28 HR HRP20200680TT patent/HRP20200680T1/hr unknown
- 2020-05-04 HR HRP20200715TT patent/HRP20200715T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR118371A2 (es) | Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina | |
CY1125089T1 (el) | Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
BR112017005104A2 (pt) | derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina | |
AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
CU20150096A7 (es) | Compuestos de amida y composición farmacéutica para el tratamiento de vih | |
EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
AR103680A1 (es) | Inhibidores selectivos de bace1 | |
BR112015022197A2 (pt) | tratamento de cataplexia | |
CO6781497A2 (es) | Tratamiento para la lipodistrofia | |
CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
EA201790234A1 (ru) | 2'-хлораминопиримидиноновые и пиримидиндионовые нуклеозиды | |
CL2018003431A1 (es) | Tratamiento de la enfermedad de parkinson. | |
WO2016057658A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
SG11201702766YA (en) | Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv) | |
EA201790632A1 (ru) | 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса | |
CR20170426A (es) | Inhibidores de bace 1 | |
AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
PH12017500492A1 (en) | Crystalline bace inhibitors | |
IL248428A0 (en) | Use of 3,1-propanedisulfonic acid or pharmaceutically acceptable saline to treat sarcoidosis | |
TR201903234T4 (tr) | Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |